Skip to main content

Table 3 Serum concentrations of vascular markers in patients with systemic sclerosis (SSc) at baseline and after nifedipine treatment

From: Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1

Serum constituent Baseline (n = 20) After nifedipine treatment (n = 20) P (Wilcoxon test)
sVCAM-1 (pg/ml) 728.7 (450–1034) 635 (312–890) P = 0.0001
Carbonyl residues (nmol/mg protein) 0.69 (0.37–1.08) 0.57 (0.33–0.86) P = 0.0006
AOPP (μmol/l of chloramine-T equivalents) 111.35 (50.5–257.6) 89.25 (28–186.4) P = 0.004
VEGF (pg/ml) 463 (26–1251) 421.5 (47–2032) P = 0.97
sVEGFR-1 (pg/ml) 46 (10–587) 32 (9–452) P = 0.43
  1. Values are median (range) of serum concentrations in patients. AOPP, advanced oxidation protein products; sVCAM-1, soluble vascular cell adhesion molecule 1; sVEGFR-1, soluble VEGF receptor 1; VEGF, vascular endothelial growth factor.